Ayrmid Ltd, the parent company of Gamida Cell Inc., has entered into an exclusive agreement with Ariti S.A., a Greek pharmaceutical company, to distribute Omisirge®, a specialized cell therapy designed for allogeneic transplants, in Greece and Cyprus. This partnership is aimed at improving patient access to advanced therapeutic solutions within these regions, leveraging Ariti's established infrastructure and expertise in hematology.

As part of the agreement, Ariti will implement early access schemes for Omisirge, which will facilitate patient access to this innovative treatment. The CEO of Ayrmid, Dr. Joe Wiley, emphasized that this collaboration is a significant milestone in broadening the reach of essential medical therapies to new markets. This is particularly important in enhancing treatment options for patients facing serious health challenges related to blood disorders requiring transplants.

The CEO of Ariti S.A., Serafim Kyrkos, highlighted that this partnership brings together Ariti's longstanding experience in hematology with Ayrmid's innovative therapies, including Omisirge®. Such collaboration is expected to enrich the therapeutic landscape in Greece and Cyprus, providing patients with timely access to cutting-edge treatments, and underscores the commitment of both companies to improving healthcare outcomes in their regions.